



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

## Anti-IL-13 [CNTO607] Bulk Size Ab03211-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

**Isotype and Format:** Human IgG1, Fc Silent™, Lambda

**Clone Number:** CNTO607

**Alternative Name(s) of Target:** IL13; NC30; Interleukin-13; MOR3406

**UniProt Accession Number of Target Protein:** P35225

**Published Application(s):** neutralize, ELISA

**Published Species Reactivity:** Human

**Immunogen:** The original antibody was generated from Morphosys HuCAL-Gold™ phage display library after panning against an IL-13 variant (R130Q) identified in a sub-population of patients who suffer from asthmatic attacks.

**Specificity:** This antibody binds an epitope at the surface formed by helices A and D of human interleukin-13. This epitope overlaps with the IL-4Ralpha/IL-13Ralpha1 receptor-binding site, which explains the neutralizing effect of CNTO607. IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, natural killer T cell, mast cells, basophils, eosinophils and nuocytes. It inhibits the production of inflammatory cytokines (IL-1, IL-6, TNF, IL-8) by LPS-stimulated monocytes. It synergizes with IL2 in regulating interferon-gamma synthesis. It is a mediator of allergic inflammation and different diseases including asthma.

**Application Notes:** The original IgG1 version of this antibody binds human IL-13 with an affinity of 18pM and prevents binding of IL-13 to both IL-13Rα1 and IL-4Rα. This antibody can bind native wild type and recombinant human IL-13 in an ELISA (PMID: 19361524). This antibody is capable of neutralizing IL13 activity in the TF-1 and in the IL-13Rα1 receptor binding assay (US20080044420). This antibody has the tendency to self associate. The IgG1 version of this antibody can be concentrated to ~13 mg/ml before irreversible precipitation occurs (PMID: 22915597). The relative binding affinity of the IgG1 version of this antibody was determined to be 18.4 pM (PMID: 22915597).

**Antibody First Published in:** Teplyakov et al. Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607. J Mol Biol. 2009 May 29;389(1):115-23. [PMID:19361524](#)

**Note on publication:** Describes the epitope mapping of this antibody using X-ray crystallography..

## Product Form

**Size:**

1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.